Proteomics is elaborated as the large-scale characterization of the entire protein supplement of an organism, tissue, or cell line. It is used to study the dynamic protein products of the genome and their products. Proteomics identifies and characterizes the resolved proteins by mass spectrometry, a fast and non-invasive diagnostics tool for patients with various diseases. It is highly adapted to identify potential new drugs for the treatment of diseases through the analysis of human genes and the structure of the protein. Also, researchers are expected to use these techniques to develop personalized drugs that are more effective for the individual as every individual has genetic differences. Proteomics-based technologies are involved in various applications, such as understanding pathogenicity mechanisms, candidates for vaccine production, detections of various diagnostic markers, interpretation of functional protein pathways in different diseases, and alteration of expression patterns in response to different signals. Proteomics-based technologies are involved in various applications, such as understanding pathogenicity mechanisms, candidates for vaccine production, detections of various diagnostic markers, interpretation of functional protein pathways in different diseases, and alteration of expression patterns in response to different signals. Various bioinformatics tools are used to handle an enormous quantity of data and its storage and prediction of 3D structure and microarray chips for high-throughput and rapid expression analysis.
The global proteomics market size was valued at $21,122.32 million in 2019 and projected to reach $49,978.8 million by 2027, growing at a CAGR of 12.2% during the forecast period, 2020-2027. The major factors are the growing demand for proteomics for early disease diagnosis and prognosis. Additionally, the increasing R&D investments by pharmaceutical& biotechnology companies will spur the global proteomics industry in the future periods. Furthermore, the growing public-private funding for proteomics-based research activities and the easy development of conventional techniques for protein purification is expected to witness remarkable growth of proteomics. The increasing clinical usage of proteomics in pharmacology, such as drug discovery &development or drug target identification, biomarker discovery, and personalized medicines, is expected to propel the demand for proteomics over the coming years.
Moreover, the upsurge in demand for proteomics for screening and treatment of numerous diseases, including blood-related diseases, cancer, diabetes, cardiovascular disorders, and other infectious diseases, positively impacts the market for proteomics in the healthcare industry. Furthermore, the rapid expansion in customer base, rise in the extensive R&D activities at the academic and industrial level, and increasing scope of biomedical applications are fueling the demand for proteomics in the healthcare market. The growing applications of proteomics in the food industry for quality control and safety of raw materials with the detection of allergens origin will bolster the global proteomics market share growth. Additionally, the growing population and increasing healthcare demands in the developing world swelling the growth of the proteomics market across the globe.
In clinical research, proteomics is a highly adaptable tool for exploring cellular pathways and disease processes. Technological and scientific advancements in MS and bioinformatics have facilitated novel applications of clinical proteomics in drug development, biomarker discovery, and disease etiology. Moreover, Pharmaceutical & biotechnology companies are considering the identification of novel therapeutic biomarkers in clinical trials. However, the path from clinical testing to regulatory approval of new drugs is a long and expensive process and can be considered as a restraint to the market. Moreover, the improved sensitivity, speed, and resolution of the techniques enable a high-throughput proteomic analysis of complex biological samples. Additionally, the advances in instrumentation enabled a higher scanning rate and became an essential tool for biomedical scientists.
Like MS technology, Nanopore sensing provides benefits to researchers to stretch the idea of protein fingerprinting or 3D fingerprinting to identify whole proteins by measuring the volume and the shape, rotational diffusion coefficient, charge, and dipole moment and also identifies specific protein much easily.
Recently, the outbreak of COVID-19 has vigorously affected the healthcare system of developed and developing countries globally. The growing nervousness regarding the shortage of essential medical life-saving devices and other necessary medical supplies to prevent the spread of this virus and provide optimum care to the infected also widens. Additionally, the growing need for the clinical diagnosis will enhance the demand for proteomics in the healthcare industry.
Based on the technology, the global proteomics market is segregated into protein fractionation, protein microarrays, spectroscopy, x-ray crystallography, chromatography, electrophoresis, and surface plasmon resonance.
The protein fractionation segment is estimated to witness the highest growth over the analysis timeframe due to the advantage of effectively separating thousands of proteins in a complex structure & high resolution and also reduces sample complexity.
The Microarray will grow significantly due to the ability to parallel quantification of thousands of genes from multiple samples and rising adoption of proteomics systems and provides the advantage of label-free detection and absolute quantification.
Based on the reagents, the global proteomics market is categorized into protein fractionation reagents, protein microarray reagents, spectroscopy reagents, x-ray crystallography reagents, chromatography reagents, electrophoresis reagents, and immunoassay reagents.
The protein fractionation reagents segment is held for a significant market share in 2019 and will gain maximum market revenue by 2027. It is attributable to the widespread use across the research institutes for the effective analysis of various biological samples and the rising need for protein separation.
The protein microarray reagents segment is poised to witness significant growth over the forecast period. It doesn’t require a large sample to give more information and the rising frequency of usage in academic institutions.
Based on the software & services, the global proteomics market is classified into core proteomics services and bioinformatics software.
The Core Proteomics Services are expected to be the highest revenue share for proteomics during the forecast period. The segment’s growth is primarily assigned to the growing adaptation at every stage of protein identification &analysis and the high requirement of peptide synthesis and emerging needs of outsourcing.
The Bioinformatics software will witness a lucrative growth rate in the estimated period due to easy handling & maintenance of data and the rising need for 3D structure prediction in drug discovery.
The global proteomics market is attached to drug discovery, clinical diagnostics, and other applications based on the applications.
The clinical diagnostics segment will dominate the global proteomics market by 2027. It is due to the rise in prevalence of cancer & other Infectious diseases and the rising demand for disease biomarker discovery.
Drug discovery accounted for the largest share of the proteomics market in 2019 because of the increasing demand for personalized medicine and the identification of targeted drugs.
The global proteomics market is segmented into North America, Europe, Asia Pacific, South America, and Middle East & Africa by geography. North America is estimated to project considerable patients over 2020-2026. It is owing to advents in technology, the presence of leading industry players offering innovative products, and increasing demand for high-quality research tools for data reproducibility.
The Asia Pacific will capture a leading share of the proteomics market by 2027. Due to the increasing awareness for new technologies, rising focus on developing personalized therapeutics, and mounting health care expenditures in emerging countries such as India and China.
Companies such as GE Healthcare, Bio-Rad Laboratories Inc., Waters Corporation, PerkinElmer Inc., Thermo Fisher Scientific Inc, Agilent Technologies, Danaher Corporation, Bruker Corporation, Luminex Corporation, Merck KGaA, Promega Corporation, and Creative Proteomics are the key players in the global proteomics market.
By Software & Services